Current Report Filing (8-k)
10 December 2020 - 09:22AM
Edgar (US Regulatory)
0001000694
false
0001000694
2020-12-05
2020-12-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): December 5, 2020
NOVAVAX, INC.
(Exact name of registrant as specified
in charter)
Delaware
|
|
0-26770
|
|
22-2816046
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
21 Firstfield Road
Gaithersburg, Maryland 20878
(Address of Principal Executive Offices,
including Zip Code)
(240) 268-2000
(Registrant’s telephone number,
including area code)
(Former name or former address, if changed
since last report.)
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, Par Value $0.01 per share
|
|
NVAX
|
|
The Nasdaq Global Select Market
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment
of Director Margaret G. Mcglynn
On December 5, 2020, the Board of Directors
(the “Board”) of Novavax, Inc. (the “Company”) voted to increase the size of the Board from nine members
to ten members and to appoint Margaret G. Mcglynn to the Board to fill the resulting vacancy, effective as of December 7, 2020.
Ms. Mcglynn will serve as a Class II director and her term will expire at the Company’s 2021 annual meeting of stockholders.
The Board has not appointed Ms. Mcglynn to any Board committees at this time. Ms. Mcglynn will receive an annual retainer of $40,000
for her service on the Board. Ms. Mcglynn was granted a stock option award of 7,700 shares of Company common stock under the Company’s
Amended and Restated 2015 Stock Incentive Plan, as amended. There is no arrangement or understanding between Ms. Mcglynn and any
other person pursuant to which Ms. Mcglynn was selected as a director. The Board has affirmatively determined that Ms. Mcglynn
is independent and has no material direct or indirect interest in a related party transaction that requires disclosure. Ms. Mcglynn
and the Company have entered into an indemnification agreement (the “Indemnification Agreement”) which will provide
indemnification protection for Ms. Mcglynn in connection with her service as a director of the Company. The Indemnification Agreement
is substantially similar to the form filed as Exhibit 10.19 to the Company’s Annual Report on Form 10-K for the year ended
December 31, 2009, filed on March 16, 2010 and incorporated herein by reference.
On December 9,
2020, the Company issued a press release announcing Ms. Mcglynn’s appointment to the Board. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Novavax, Inc.
|
|
|
|
Date: December 9, 2020
|
By:
|
|
/s/ John A. Herrmann III
|
|
Name:
|
|
John A. Herrmann III
|
|
Title:
|
|
Executive Vice President, Chief Legal Officer and Corporate Secretary
|
|
|
|
|
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2023 to Mar 2024